MicroRNA-542-3p inhibits the growth of hepatocellular carcinoma cells by targeting FZD7/Wnt signaling pathway

Biochemical and Biophysical Research Communications

Volumn 482, Issue 1, 2017, Pages 100-105

  Wu, Wenhua ^a   Dang, Shuangsuo ^a   Feng, Qinhui ^b   Liang, Junrong ^c   Wang, Yuan ^a   Fan, Na ^a  

^a THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

FZD7; Hepatocellular carcinoma; miR 542 3p; Wnt signaling pathway

Indexed keywords

FRIZZLED 7 PROTEIN; FRIZZLED PROTEIN; MESSENGER RNA; MICRORNA; MICRORNA 542 3P; UNCLASSIFIED DRUG; WNT PROTEIN; FZD7 PROTEIN, HUMAN; MIRN542 MICRORNA, HUMAN;

ARTICLE; CANCER GENETICS; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROTEIN RNA BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR PROMOTION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; CELL PROLIFERATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; FRIZZLED RECEPTORS; HUMANS; MICRORNAS; WNT SIGNALING PATHWAY;

EID: 85006168210     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.10.136     Document Type: Article

References (40)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
2. [2] Chen, W., Zheng, R., Baade, P.D., et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66 (2016), 115–132.
3. [3] Schwartz, M., Roayaie, S., Konstadoulakis, M., Strategies for the management of hepatocellular carcinoma. Nat. Clin. Pract. Oncol. 4 (2007), 424–432.
4. [4] Idilman, R., De Maria, N., Colantoni, A., et al. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J. Viral Hepat. 5 (1998), 285–299.
5. [5] Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
6. [6] Winter, J., Jung, S., Keller, S., et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat. Cell Biol. 11 (2009), 228–234.
7. [7] Schickel, R., Boyerinas, B., Park, S.M., et al. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27 (2008), 5959–5974.
8. [8] Lin, S., Gregory, R.I., MicroRNA biogenesis pathways in cancer. Nat. Rev. Cancer 15 (2015), 321–333.
9. [9] Hayes, J., Peruzzi, P.P., Lawler, S., MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 20 (2014), 460–469.
10. [10] Li, X., Yang, W., Lou, L., et al. microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Dig. Dis. Sci. 59 (2014), 1099–1107.
11. [11] Chang-Hao Tsao, S., Behren, A., Cebon, J., et al. The role of circulating microRNA in hepatocellular carcinoma. Front. Biosci. (Landmark Ed.) 20 (2015), 78–104.
12. [12] Abu-Elmagd, M., Garcia-Morales, C., Wheeler, G.N., Frizzled7 mediates canonical Wnt signaling in neural crest induction. Dev. Biol. 298 (2006), 285–298.
13. [13] Reya, T., Clevers, H., Wnt signalling in stem cells and cancer. Nature 434 (2005), 843–850.
14. [14] Klaus, A., Birchmeier, W., Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 8 (2008), 387–398.
15. [15] King, T.D., Zhang, W., Suto, M.J., et al. Frizzled7 as an emerging target for cancer therapy. Cell Signal. 24 (2012), 846–851.
16. [16] Yang, L., Wu, X., Wang, Y., et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 30 (2011), 4437–4446.
17. [17] Deng, B., Zhang, Y., Zhang, S., et al. MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7. Tumour Biol. 36 (2015), 8065–8073.
18. [18] Merle, P., Kim, M., Herrmann, M., et al. Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J. Hepatol. 43 (2005), 854–862.
19. [19] Nambotin, S.B., Lefrancois, L., Sainsily, X., et al. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J. Hepatol. 54 (2011), 288–299.
20. [20] Rang, Z., Yang, G., Wang, Y.W., et al. miR-542-3p suppresses invasion and metastasis by targeting the proto-oncogene serine/threonine protein kinase, PIM1, in melanoma. Biochem. Biophys. Res. Commun. 474 (2016), 315–320.
21. [21] Cai, J., Zhao, J., Zhang, N., et al. MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma. J. Biol. Chem. 290 (2015), 24678–24688.
22. [22] Phesse, T., Flanagan, D., Vincan, E., Frizzled7: a promising Achilles' heel for targeting the Wnt receptor complex to treat Cancer. Cancers (Basel), 8, 2016.
23. [23] Anwar, S.L., Lehmann, U., MicroRNAs: emerging novel clinical biomarkers for hepatocellular carcinomas. J. Clin. Med. 4 (2015), 1631–1650.
24. [24] Mao, B., Wang, G., MicroRNAs involved with hepatocellular carcinoma (Review). Oncol. Rep. 34 (2015), 2811–2820.
25. [25] Yoon, S., Choi, Y.C., Lee, S., et al. Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett. 584 (2010), 4048–4052.
26. [26] Wang, S., Zhu, L., Zuo, W., et al. MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget 7 (2016), 37693–37713.
27. [27] Zhang, J., Wang, S., Han, F., et al. MicroRNA-542-3p suppresses cellular proliferation of bladder cancer cells through post-transcriptionally regulating survivin. Gene 579 (2016), 146–152.
28. [28] Althoff, K., Lindner, S., Odersky, A., et al. miR-542-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. Int. J. Cancer 136 (2015), 1308–1320.
29. [29] He, T., Qi, F., Jia, L., et al. MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J. Pathol. 232 (2014), 499–508.
30. [30] Shen, X., Si, Y., Yang, Z., et al. MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1. Med. Oncol., 32, 2015, 361.
31. [31] Long, H.C., Gao, X., Lei, C.J., et al. miR-542-3p inhibits the growth and invasion of colorectal cancer cells through targeted regulation of cortactin. Int. J. Mol. Med. 37 (2016), 1112–1118.
32. [32] Wong, C.M., Fan, S.T., Ng, I.O., beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92 (2001), 136–145.
33. [33] Merle, P., de la Monte, S., Kim, M., et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 127 (2004), 1110–1122.
34. [34] Kim, M., Lee, H.C., Tsedensodnom, O., et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J. Hepatol. 48 (2008), 780–791.
35. [35] Wei, W., Chua, M.S., Grepper, S., et al. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol. Cancer, 10, 2011, 16.
36. [36] Deng, B., Zhang, Y., Zhang, S., et al. MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7. Tumour Biol. 36 (2015), 8065–8073.
37. [37] Ren, W., Li, C., Duan, W., et al. MicroRNA-613 represses prostate cancer cell proliferation and invasion through targeting Frizzled7. Biochem. Biophys. Res. Commun. 469 (2016), 633–638.
38. [38] Geng, Y., Lu, X., Wu, X., et al. MicroRNA-27b suppresses Helicobacter pylori-induced gastric tumorigenesis through negatively regulating Frizzled7. Oncol. Rep. 35 (2016), 2441–2450.
39. [39] Song, J., Gao, L., Yang, G., et al. MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One, 9, 2014, e110074.
40. [40] Chen, Z., Ma, T., Huang, C., et al. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/beta-catenin pathway in hepatocellular carcinoma cells. Cell Signal. 25 (2013), 2693–2701.